Stock AnalizEnvista Holdings Corp NVST
Medical/Dental Instruments · IPO 2019 · data as of November 13, 2026
Envista Holdings Corp (NVST) is a healthcare company listed in the US with a market value of about $3.9B. In the twelve months to October 2, 2026 it had revenue of $2.9B and net income of $634M, a net margin of 22.0%.
Its overall Stock Analiz score is 2.4 out of 5 (weak). The strongest part is value (4/5); the weakest is track record (0/5).
Key numbers: a P/E of 6.3, a price to free cash flow of 16.2, 5-year revenue growth of 7% a year, a 5-year average ROIC of -1%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 24% below the current price.
Score: 2.4 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- PEG below 1.5
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Positive free cash flow
- Interest covered more than 5 times
Checks not passed
- Price below intrinsic value (DCF, moderate assumptions)
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
Valuation
Growth and quality
Financials, last 9 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.9B | $2.7B | $2.5B | $2.6B | $2.6B | $2.5B | $1.9B | $2.3B | $2.8B | $2.8B |
| Net income | $634M | $47M | -$1.1B | -$100M | $243M | $340M | $33M | $218M | $231M | $301M |
| Free cash flow | $242M | $230M | $303M | $218M | $107M | $307M | $236M | $320M | $328M | $310M |
| EPS (diluted) | $3.87 | $0.28 | $-6.50 | $-0.60 | $1.37 | $1.92 | $0.20 | $1.60 | $1.80 | $2.35 |
| Net margin | 22.0% | 1.7% | -44.6% | -3.9% | 9.5% | 13.6% | 1.7% | 9.5% | 8.1% | 10.7% |
| ROIC | — | 3.6% | -18.3% | 0.4% | 4.7% | 4.4% | 0.6% | 3.7% | 4.6% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 13 analysts is $28.92, 18% above the current price; targets range from $23.00 to $32.00; the consensus rating is “Buy”; expected EPS is $1.56 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Envista Holdings’s P/E ratio?
About 6.3, based on the last twelve months of diluted earnings per share (forward P/E about 15.1).
Is Envista Holdings stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 24% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Envista Holdings pay a dividend?
Not currently.
Is Envista Holdings a good stock to buy?
We do not give buy or sell advice. Envista Holdings scores 2.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.